Literature DB >> 15259024

Functional expression of CD134 by neutrophils.

Ralf Baumann1, Shida Yousefi, Dagmar Simon, Stefan Russmann, Christoph Mueller, Hans-Uwe Simon.   

Abstract

CD134 (OX40) is a member of the tumor necrosis factor (TNF) receptor superfamily expressed on activated T cells. Here, we show that human peripheral blood neutrophils express CD134. Activation of CD134 by soluble CD134 ligand (OX40 ligand/gp34) resulted in delayed caspase-3 activation and consequently in delayed neutrophil apoptosis in vitro. Moreover, CD134 ligand, like G-CSF, maintained anti-apoptotic Mcl-1 levels and inhibited cleavage of the pro-apoptotic Bcl-2 family members Bid and Bax in these cells, suggesting that CD134-mediated signals block apoptosis pathways proximal to mitochondria activation. In conclusion, CD134 regulates neutrophil survival, suggesting that this molecule does not only contribute to adaptive but also to innate immune responses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15259024     DOI: 10.1002/eji.200424863

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  31 in total

Review 1.  Signaling through OX40 enhances antitumor immunity.

Authors:  Shawn M Jensen; Levi D Maston; Michael J Gough; Carl E Ruby; William L Redmond; Marka Crittenden; Yuhuan Li; Sachin Puri; Christian H Poehlein; Nick Morris; Magdalena Kovacsovics-Bankowski; Tarsem Moudgil; Chris Twitty; Edwin B Walker; Hong-Ming Hu; Walter J Urba; Andrew D Weinberg; Brendan Curti; Bernard A Fox
Journal:  Semin Oncol       Date:  2010-10       Impact factor: 4.929

Review 2.  Next generation immune-checkpoints for cancer therapy.

Authors:  Chiara Donini; Lorenzo D'Ambrosio; Giovanni Grignani; Massimo Aglietta; Dario Sangiolo
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

Review 3.  Science gone translational: the OX40 agonist story.

Authors:  Andrew D Weinberg; Nicholas P Morris; Magdalena Kovacsovics-Bankowski; Walter J Urba; Brendan D Curti
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

4.  Herpes virus entry mediator synergizes with Toll-like receptor mediated neutrophil inflammatory responses.

Authors:  Philipp Haselmayer; Stefan Tenzer; Byoung S Kwon; Gundram Jung; Hansjörg Schild; Markus P Radsak
Journal:  Immunology       Date:  2006-11       Impact factor: 7.397

Review 5.  Co-stimulatory and co-inhibitory pathways in cancer immunotherapy.

Authors:  Rachel E O'Neill; Xuefang Cao
Journal:  Adv Cancer Res       Date:  2019-04-17       Impact factor: 6.242

Review 6.  Stimulating T Cells Against Cancer With Agonist Immunostimulatory Monoclonal Antibodies.

Authors:  Xue Han; Matthew D Vesely
Journal:  Int Rev Cell Mol Biol       Date:  2018-08-20       Impact factor: 6.813

7.  CD8+ T cell-independent tumor regression induced by Fc-OX40L and therapeutic vaccination in a mouse model of glioma.

Authors:  Katherine A Murphy; Jami R Erickson; Charles S Johnson; Charles E Seiler; Jessica Bedi; Peisheng Hu; G Elizabeth Pluhar; Alan L Epstein; John R Ohlfest
Journal:  J Immunol       Date:  2013-11-29       Impact factor: 5.422

Review 8.  The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.

Authors:  Danny N Khalil; Eric L Smith; Renier J Brentjens; Jedd D Wolchok
Journal:  Nat Rev Clin Oncol       Date:  2016-03-15       Impact factor: 66.675

Review 9.  The role of OX40-mediated co-stimulation in T-cell activation and survival.

Authors:  William L Redmond; Carl E Ruby; Andrew D Weinberg
Journal:  Crit Rev Immunol       Date:  2009       Impact factor: 2.214

Review 10.  The significance of OX40 and OX40L to T-cell biology and immune disease.

Authors:  Michael Croft; Takanori So; Wei Duan; Pejman Soroosh
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.